Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 85 | 0.91 |
| pathways Reactome | 4 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 3613
Sealed predictions
- EAF2 in dopamine neurons, braak+0.32 (p 0.399) → -0.10 (p 0.802)receipt 3620
Swarm cases
receipt 3620: EAF2 in dopamine neurons, braak
- power
- full sample +0.26 (p 0.298, n 18), 95% CI -0.24 to +0.65. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.28 (p 0.269, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.38 (p 0.116, n 18). could be the mix.
- skeptic
- leave-one-out range +0.17 to +0.41, sign flips 0; without severely affected donors +0.26 (p 0.298, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for EAF2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts